Clinical

A review of data on 2 mitochondrial membrane stabilizers—risuteganib and elamipretide—has highlighted the potential to not just slow disease progression but actually reverse vision loss in patients with intermediate dry age-related macular degeneration (AMD).

For patients with geographic atrophy (GA) taking pegcetacoplan, the drug’s effect to slow disease progression increases over time as patients take the drug, said Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment.

Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results.

Joseph Coney, MD, FASRS, FACS, discusses the difference between population groups in age-related macular degeneration (AMD) and diabetic macular edema (DME)

Jim Kenney, RPh, MBA, opens a discussion surrounding wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

The Angiogenesis, Exudation, and Degeneration 2023 meeting will be held virtually with a program focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye.

In the final discussion, expert panelists navigate treatment sequencing in MM treatment strategies.

Dr Nadeem provides community and clinical strategies to treat patients with MM.

Callie Coombs, MD, discusses how pirtobrutinib (LOXO-305), a Bruton tyrosine kinase inhibitor (BTKi) being investigated in the BRUIN trial, might impact the BTKi landscape.

Brian Koffman, MD, reviews how Bruton tyrosine kinase inhibitors are addressing unmet needs in chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and what unmet needs remain.

The effects of physical activity and exercise have previously been reported, with data pointing to improvements in quality of life as well as such clinical markers as immune response in tumors

The method had high rates of sensitivity and specificity, although its sensitivity was somewhat lower in cases of localized prostate cancer.

Maria Lopes, MD, MS, reviews how to educate providers on the risks and burdens of psoriasis and how to improve early diagnosis and treatment for all skin phototypes and ethnicities.

Bruce Sherman, MD, FCCP, FACOEM, underlines how to support patients financially to afford therapies and maintain adherence.

Data from 2 prospective studies showed correlations between impaired patient health-related quality of life (HRQOL) and disease severity, as well as correlations between the health of caregivers and their HRQOL and caregiver burden.

Dr Brinton provides an overview of guideline-directed therapies in HoFH.

Seth Baum, MD, and Erin Michos, MD, MHS, discuss pediatric diagnosis of homozygous FH.

A novel test developed at Cedars-Sinai Medical Center was able to detect and characterize even microscopic amounts of prostate cancers and could potentially help individualize treatment in the clinical setting.

Having models like these that produce more plausible results are crucial for decision-making in an era of targeted treatments that often come with immature data, argued researchers of their findings for minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM).

The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.

The study suggests there is measurable amount of microbiome within the soft tissue sarcoma tumor environment, which was previously thought to be sterile.

In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS.

Dr De Castro explores considerations surrounding cost in treatment of PNH.

Known to be a contributing factor to polyp development at high levels, periostin’s potential as a biomarker for eosinophilic chronic rhinosinusitis (ECRS) severity was investigated in a new study in which outcomes were compared between patients who had ECRS and those with non-ECRS.